About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

11 comments

  • I understand the need to include people in wheel chairs. But this goes back to your own previous arguments when EDSS is high the damage is all ready irreversible. So how would money grabbing pharma see a return on their over inflated clinical trial cost? How would they set their primary and secondary outcomes? That's why your proposal to do the caldribine trial for primary progressive will never get off the ground at cost of 2 million. Once it's proven to governments trials can be done a lot cheaper. Pharma stranglehold on health spending will be broken. But hey good luck!

  • Very clever!

    My prediction is that Three Billboards is going to take the big one at the Oscars. Let's hope you do the same with #ThinkHand.

  • "The current list of meds has not shown efficacy so far."

    Yes..these dmt meds are all far too oblique in targeting disease process resulting in therapeautic lag of 2-4 years..yes years. If
    they don't work the first time on the legs it seems doubtful they
    will do much better on the shorter length hands in a second go round.

    If they did save hands in progressive ms someone in clinical practice
    should have discovered this by now because there are no prescription limitations for people on u.s. govt. disability.

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives